Safety and efficacy of B-Cell Receptor inhibitors (ibrutinib or idelalisib) with or without venetoclax in patients with chronic lymphocytic leukemia
Latest Information Update: 22 Jul 2020
At a glance
- Drugs Ibrutinib (Primary) ; Idelalisib (Primary) ; Venetoclax
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions; Therapeutic Use
- 22 Jul 2020 New trial record
- 21 Jun 2020 Results presented at the 25th Congress of the European Haematology Association